GILLIAN SANDERS

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Evaluating human papillomavirus vaccination programs
    Al V Taira
    Stanford School of Medicine, Stanford, California, USA
    Emerg Infect Dis 10:1915-23. 2004
  2. pmc Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
    Alex R Kemper
    Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA
    BMC Pediatr 12:29. 2012
  3. ncbi request reprint Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke Medical Center, Durham, NC 27715, USA
    Am Heart J 153:951-9. 2007
  4. ncbi request reprint Cost-effectiveness of implantable cardioverter-defibrillators
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    N Engl J Med 353:1471-80. 2005
  5. ncbi request reprint Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    N Engl J Med 352:570-85. 2005
  6. doi request reprint Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Am Heart J 160:122-31. 2010
  7. pmc Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 25:556-63. 2010
  8. pmc Cost-effectiveness of HIV screening in patients older than 55 years of age
    Gillian D Sanders
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Ann Intern Med 148:889-903. 2008
  9. pmc Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials
    Sana M Al-Khatib
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 309:55-62. 2013
  10. doi request reprint Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis
    Jonathan P Piccini
    Duke Clinical Research Institute and the Duke University School of Medicine, Durham, North Carolina 27705, USA
    J Cardiovasc Electrophysiol 21:791-8. 2010

Detail Information

Publications45

  1. pmc Evaluating human papillomavirus vaccination programs
    Al V Taira
    Stanford School of Medicine, Stanford, California, USA
    Emerg Infect Dis 10:1915-23. 2004
    ..Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared to female-only vaccination...
  2. pmc Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
    Alex R Kemper
    Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA
    BMC Pediatr 12:29. 2012
    ..g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids). The purpose of this systematic review was to evaluate the comparative effectiveness and safety of DMARDs versus conventional therapy and versus other DMARDs...
  3. ncbi request reprint Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke Medical Center, Durham, NC 27715, USA
    Am Heart J 153:951-9. 2007
    ....
  4. ncbi request reprint Cost-effectiveness of implantable cardioverter-defibrillators
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    N Engl J Med 353:1471-80. 2005
    ..We assessed the cost-effectiveness of the ICD in the populations represented in these primary-prevention trials...
  5. ncbi request reprint Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    N Engl J Med 352:570-85. 2005
    ..The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined...
  6. doi request reprint Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Am Heart J 160:122-31. 2010
    ..We sought to examine the cost-effectiveness of ICD therapy in at-risk patients >or=65 years old...
  7. pmc Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 25:556-63. 2010
    ..The CDC recommends routine voluntary HIV testing of all patients 13-64 years of age. Despite this recommendation, HIV testing rates are low even among those at identifiable risk, and many patients do not return to receive their results...
  8. pmc Cost-effectiveness of HIV screening in patients older than 55 years of age
    Gillian D Sanders
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Ann Intern Med 148:889-903. 2008
    ..Recent guidelines recommend HIV screening in patients age 13 to 64 years. The cost-effectiveness of HIV screening in patients age 55 to 75 years is uncertain...
  9. pmc Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials
    Sana M Al-Khatib
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 309:55-62. 2013
    ..Whether the survival of patients who received an ICD in primary prevention clinical trials differs from that of trial-eligible patients receiving a primary prevention ICD in clinical practice is unknown...
  10. doi request reprint Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis
    Jonathan P Piccini
    Duke Clinical Research Institute and the Duke University School of Medicine, Durham, North Carolina 27705, USA
    J Cardiovasc Electrophysiol 21:791-8. 2010
    ..The optimal timing of implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death after myocardial infarction (MI) remains unknown...
  11. pmc Systematic review of the incidence of sudden cardiac death in the United States
    Melissa H Kong
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 57:794-801. 2011
    ..S. population...
  12. doi request reprint Do physicians' attitudes toward implantable cardioverter defibrillator therapy vary by patient age, gender, or race?
    Sana M Al-Khatib
    Duke Cardiovascular Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC, USA
    Ann Noninvasive Electrocardiol 16:77-84. 2011
    ..We assessed whether physicians' recommendation for ICD therapy varies as a function of patient age, gender, race, and physician's specialty...
  13. pmc Non-evidence-based ICD implantations in the United States
    Sana M Al-Khatib
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 305:43-9. 2011
    ....
  14. pmc An economic evaluation of prolonged mechanical ventilation
    Christopher E Cox
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Duke University, Durham, NC, USA
    Crit Care Med 35:1918-27. 2007
    ..Therefore, we aimed to determine the lifetime societal value of prolonged mechanical ventilation...
  15. doi request reprint Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 111:179-87. 2008
    ..We wished to estimate the clinical impact and cost-effectiveness of potential screening strategies for ovarian cancer using population-specific data...
  16. pmc Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies
    Melissa H Kong
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 160:605-18. 2010
    ..This article summarizes the discussions that occurred at the meeting...
  17. doi request reprint Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention
    Sana M Al-Khatib
    The Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 156:613-22. 2008
    ..Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred at the meeting presents the expert opinion of the authors...
  18. doi request reprint Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Cardiovasc Electrophysiol 21:545-50. 2010
    ..We sought to determine whether remote monitoring of ICDs improves patient outcomes compared with quarterly device interrogations in clinic...
  19. ncbi request reprint Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death
    Sana M Al-Khatib
    The Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 153:941-50. 2007
    ..This article summarizes the presentations and discussions that occurred at that meeting...
  20. doi request reprint Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 117:545-53. 2011
    ..The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies...
  21. ncbi request reprint Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004
    Sana M Al-Khatib
    The Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 149:1020-34. 2005
    ..This document summarizes the evidence reviewed at that meeting and the discussions of that evidence...
  22. doi request reprint Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease
    Ahmed M Bayoumi
    Center for Research on Inner City Health, The Keenan Research Center in the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada Department of Medicine, University of Toronto, Toronto, Ontario, Canada Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada Division of General Internal Medicine, St Michael s Hospital, Toronto, Ontario, Canada VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR and D Health Economics Resource Center, Menlo Park, CA Center for Health Economics, University of York, York, United Kingdom Center for Health Evaluation and Outcome Sciences, St Paul s Hospital, Vancouver, British Columbia, Canada CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada VA Palo Alto Health Care System, Palo Alto, CA Department of Medicine, Stanford University, Stanford, CA Duke Clinical Research Institute, Duke University, Durham, Cancer Research UK
    J Acquir Immune Defic Syndr 64:382-91. 2013
    ..Newer antiretroviral drugs provide substantial benefits but are expensive. The cost-effectiveness of using antiretroviral drugs in combination for patients with multidrug-resistant HIV disease was determined...
  23. doi request reprint Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction
    Nancy M Allen LaPointe
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 4:146-51. 2011
    ..The extent and documented reasons for nonuse of ICDs among patients with left ventricular systolic dysfunction are unknown...
  24. pmc Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection
    David P Holland
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Respir Crit Care Med 179:1055-60. 2009
    ..Shorter course regimens and regimens using directly observed therapy result in improved adherence but have higher upfront costs...
  25. ncbi request reprint Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis
    Robert A Fowler
    Division of General Medicine and Critical Care Medicine, Department of Medicine, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
    J Crit Care 18:181-91; discussion 191-4. 2003
    ..To evaluate the cost-effectiveness of recombinant human activated protein C (rhAPC) compared with usual therapy for patients with severe sepsis, and also to determine the influence that severity of illness exerts on cost-effectiveness...
  26. ncbi request reprint Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis
    Andrew D Auerbach
    Department of Medicine, University of California, San Francisco, CA 94143 0131, USA
    Am J Med 116:816-28. 2004
    ..We sought to determine the cost-effectiveness of testing for these disorders, as well as which tests should be selected and how results should be used...
  27. ncbi request reprint Cost-effectiveness of the implantable cardioverter defibrillator
    Mark A Hlatky
    Department of Health Research and Policy, Stanford University School of Medicine, CA 94305 5405, USA
    Card Electrophysiol Rev 7:479-82. 2003
    ..A rough rule of thumb is that the ICD will be economically attractive when it prolongs mean survival by six months or more, which is attainable in higher risk patient subgroups...
  28. pmc Cost-effectiveness of a potential vaccine for human papillomavirus
    Gillian D Sanders
    Center for Primary Care and Outcomes Research, 117 Encina Commons, Stanford University, Stanford, CA 94305 6019, USA
    Emerg Infect Dis 9:37-48. 2003
    ..If the vaccine efficacy rate is 35%, the cost effectiveness increases to $52,398/QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial...
  29. pmc Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis
    Eran Bendavid
    Center for Health Policy and the Center for Primary Care and Outcomes Research, School of Medicine, Stanford University, 117 Encina Commons, Stanford, CA 94305, USA
    Arch Intern Med 168:1910-8. 2008
    ..Although the number of infected persons receiving highly active antiretroviral therapy (HAART) in low- and middle-income countries has increased dramatically, optimal disease management is not well defined...
  30. ncbi request reprint Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax
    Robert A Fowler
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Ann Intern Med 142:601-10. 2005
    ..Weaponized Bacillus anthracis is one of the few biological agents that can cause death and disease in sufficient numbers to devastate an urban setting...
  31. ncbi request reprint Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator
    Douglas K Owens
    VA Health Care System, Palo Alto, Calif 94304, USA
    Am Heart J 144:440-8. 2002
    ..We evaluated whether risk stratification based on risk of sudden cardiac death alone was sufficient to predict the effectiveness and cost-effectiveness of the ICD...
  32. doi request reprint Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis
    Chrysoula Dosiou
    Division of Endocrinology, Department of Medicine, Stanford University Medical Center, 300 Pasteur Drive, S025, Stanford, California 94305, USA
    Eur J Endocrinol 158:841-51. 2008
    ..Our objective was to examine the cost-effectiveness of screening pregnant women for autoimmune thyroid disease...
  33. ncbi request reprint Perinatal screening for group B streptococci: cost-benefit analysis of rapid polymerase chain reaction
    Corinna A Haberland
    Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California 94305, USA
    Pediatrics 110:471-80. 2002
    ..To evaluate the costs and benefits of a group B streptococci screening strategy using a new, rapid polymerase chain reaction test in a hypothetical cohort of expectant mothers in the United States...
  34. ncbi request reprint Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus
    Rohini Vij
    Division of Gastroenterology and Hepatology, Center for Primary Care and Outcomes Research, Department of Medicine, Stanford University School of Medicine, California, USA
    Gastrointest Endosc 60:739-56. 2004
    ..Our aim was to identify the most effective and cost-effective strategy for managing high-grade dysplasia in Barrett's esophagus without associated endoscopically visible abnormalities...
  35. pmc Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV
    Douglas K Owens
    VA Palo Alto Health Care System, Palo Alto, Calif, USA
    Am J Public Health 97:2173-8. 2007
    ..We sought to determine the prevalence of HIV in both inpatient and outpatient settings in 6 Department of Veterans Affairs (VA) health care sites...
  36. ncbi request reprint Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia
    Elisa F Long
    Department of Management Science and Engineering, Stanford University, Stanford, CA 94305, USA
    AIDS 20:2207-15. 2006
    ..To assess the effectiveness and cost-effectiveness of treating HIV-infected injection drug users (IDUs) and non-IDUs in Russia with highly active antiretroviral therapy HAART...
  37. ncbi request reprint Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism
    Daniella J Perlroth
    Department of Medicine, School of Medicine, Stanford University, Stanford, California, USA
    Arch Intern Med 167:74-80. 2007
    ..Thrombolytic therapy is controversial in patients with submassive pulmonary embolism...
  38. ncbi request reprint Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules
    Michael K Gould
    Pulmonary Section, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, California 94304, USA
    Ann Intern Med 138:724-35. 2003
    ..Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is a potentially useful but expensive test to diagnose solitary pulmonary nodules...
  39. ncbi request reprint Decision science and cervical cancer
    Scott B Cantor
    Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2003-8. 2003
    ..The ultimate objective of using decision-analytic and cost-effectiveness models is to identify ways to improve women's health at an economically reasonable cost...
  40. pmc Evidence-based practice for mere mortals: the role of informatics and health services research
    Ida Sim
    Division of General Internal Medicine, Department of Medicine and the Graduate Group in Biological and Medical Informatics, University of California San Francisco, 94143 0320, USA
    J Gen Intern Med 17:302-8. 2002
    ..We discuss 2 illustrative systems--trial banks and a web-based system to develop and disseminate evidence-based guidelines (alchemist)--and conclude with a research and training agenda...
  41. ncbi request reprint Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator
    Mark A Hlatky
    Stanford University School of Medicine, Stanford, California, USA
    Health Aff (Millwood) 24:42-51. 2005
    ....
  42. ncbi request reprint Cost-effectiveness as an outcome in randomized clinical trials
    Mark A Hlatky
    Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Clin Trials 3:543-51. 2006
    ..Economic outcomes are now included in many contemporary randomized trials and provide an additional dimension to the assessment of interventions. Economic data collection and analysis pose several methodologic challenges, however...
  43. pmc Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing
    Henry D Anaya
    Center for the Study of Healthcare Provider Behavior, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    J Gen Intern Med 23:800-7. 2008
    ..HIV rapid testing is effective in many healthcare settings, but scant research has been done within primary care settings or within the US Department of Veteran's Affairs Healthcare System...
  44. doi request reprint Policy rounds: a new series and a call for papers
    Mark Helfand
    Med Decis Making 28:169-71. 2008
  45. pmc HIV testing of at risk patients in a large integrated health care system
    Douglas K Owens
    VA Palo Alto Healthcare System, Palo Alto, CA, USA
    J Gen Intern Med 22:315-20. 2007
    ..Understanding HIV screening practices and barriers to HIV testing is an important prelude to designing successful HIV screening programs. Our objective was to evaluate current practice patterns for identification of HIV...

Research Grants6